中国·金沙9570(官方)登录入口

Be the most trusted biotech company

2019-06-21

EMA Accepted First “China-Developed” Biosimilar - Henlius HLX02 Marketing Authorization Application for Review
2019-06-17

Henlius Presented Data of Two Anti-inflammatory Candidates at EULAR 2019
2019-06-10

Henlius Attends BIO 2019
2019-04-25

Henlius Trastuzumab HLX02 Filed New Drug Application
2019-04-03

Shanghai Henlius Set to Increase Awareness of Biosimilars, in Partnership with Nature Research
2019-03-22

Global Clinical Medicine Affairs Department Needs You to Join!
2019-03-19

The 2nd Combination Immunotherapy of Henlius Received Notification of Acceptance
2019-03-01

Official Announcement! Mr. WenjieZhang is Appointed as SVP and CCO of Henlius
2019-02-25

Henlius Receives NMPA Approval for Its First Product HLX01 –The Beginning of a New Era for Biosimilar